Loading publications…
The last 5 uploaded publications
The role of miR-150-5p/E2F3/survivin axis in the pathogenesis of plasmablastic lymphoma and its therapeutic potential
Miriam Verdú-Bou, Maria João Baptista, Marcelo Lima Ribeiro, Aleix Méndez López, Núria Profitós-Pelejà, Fabian Frontzek, Gaël Roué, José Luís Mate, M. Pellicer, Pau Abrisqueta, Josep Castellví, Mariana Bastos‐Oreiro, Javier Menárguez, Miguel Alcoceba, Eva González‐Barca, Fina Climent, Antonio Salar, Juan‐Manuel Sancho, Annette M. Staiger, German Ott, Ioannis Anagnostopoulos, Manel Esteller, Georg Lenz, Gustavo Tapia, José‐Tomás Navarro (2025). The role of miR-150-5p/E2F3/survivin axis in the pathogenesis of plasmablastic lymphoma and its therapeutic potential. , DOI: https://doi.org/10.1182/bloodadvances.2025016180.
Article73 days agoData from Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non–Hodgkin Lymphoma
Marcelo Lima Ribeiro, Diana Reyes-Garau, Meritxell Vinyoles, Núria Profitós-Pelejà, Juliana C. Santos, Marc Armengol, Miranda Fernández-Serrano, Alícia Sedó Mor, Joan Josep Bech‐Serra, Pedro Blecua, Eva Musulén, Carolina de la Torre, Hari P. Miskin, Manel Esteller, Francesc Bosch, Pablo Menéndez, Emmanuel Normant, Gaël Roué (2024). Data from Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non–Hodgkin Lymphoma. , DOI: https://doi.org/10.1158/1078-0432.c.7556095.
Preprint73 days agoG protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy
Marcelo Lima Ribeiro, Núria Profitós-Pelejà, Juliana C. Santos, Pedro Blecua, Diana Reyes-Garau, Marc Armengol, Miranda Fernández-Serrano, Hari P. Miskin, Francesc Bosch, Manel Esteller, Emmanuel Normant, Gaël Roué (2023). G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy. , 14, DOI: https://doi.org/10.3389/fimmu.2023.1130052.
Article73 days agoNarazaciclib, a Differentiated CDK4/6 Antagonist, Prolongs Cell Cycle Arrest and Metabolomic Reprogramming, Enabling Restoration of Ibrutinib Sensitivity in Btki-Resistant Mantle Cell Lymphoma
Núria Profitós-Pelejà, Marcelo Lima Ribeiro, Jeronimo Parra, Miranda Fernández-Serrano, Pau Marin-Escudero, Joan Josep Bech, Carolina de la Torre, Adar Makovski Silverstein, Steve Cosenza, Steven Fruchtman, Manel Esteller, Gaël Roué (2023). Narazaciclib, a Differentiated CDK4/6 Antagonist, Prolongs Cell Cycle Arrest and Metabolomic Reprogramming, Enabling Restoration of Ibrutinib Sensitivity in Btki-Resistant Mantle Cell Lymphoma. , 142(Supplement 1), DOI: https://doi.org/10.1182/blood-2023-189838.
Article73 days agoProlonged cell cycle arrest by the CDK4/6 antagonist narazaciclib restores ibrutinib response in preclinical models of BTKi‐resistant mantle cell lymphoma
Núria Profitós-Pelejà, Marcelo Lima Ribeiro, J. Parra, Miranda Fernández-Serrano, Pau Marin-Escudero, Adar Makovski-Silverstein, Stephen C. Cosenza, Manel Esteller, Gaël Roué (2023). Prolonged cell cycle arrest by the CDK4/6 antagonist narazaciclib restores ibrutinib response in preclinical models of BTKi‐resistant mantle cell lymphoma. , 41(S2), DOI: https://doi.org/10.1002/hon.3164_414.
Article73 days ago